Oral cephradine, a new cephalosporin antibiotic whose structure is similar to that of cephalexin, was used to treat 53 episodes of urinary, bronchopulmonary and wound infections in patients presenting a disseminated cancer. Under these particular circumstances were 42% excellent responses, 21% favourable results and 37% bacteriological and clinical failures. The drug was particularly effective in treating infectoins in anatomically normal urinary-tract and wound infections. In vitro tests showed that cephradine inhibited most strains of Pneumococcus Staphylococcus and Streptococcus pyogenes. The susceptibility to cephradine of Enterobacteriaceae was more variable. A zone of growth inhibition of 20 mm or more around a 30-μ g cephradine disc was a good indication of drug sensitivity for most bacterial species tested. This study suggests that oral cephradine is a valuable alternative drug for the treatment of many bacterial infections that are usually treated by the oral route. Further studies should establish the optimal dosage of cephradine and compare this drug to other antimicrobial agents.

Keywords:
Cephradine, Cephalosporins, Different infections, Cancer patients, Bacteriology, Pharmacokinetics
This content is only available via PDF.
© 1973 S. Karger AG, Basel
1973
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.